Annovis Bio: Funding, Investors & Team (Sep 2026)
Annovis Bio is a pharmaceutical company focused on creating new therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. They are working on two drugs: Posiphen®, which aims to treat early stages of AD and PD to potentially slow the disease progression, and BNC, which targets late-stage AD to potentially stabilize cognitive decline.
Annovis Bio has raised $58.1M across 5 funding rounds on record, the most recent an undisclosed round of $15.0M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Annovis Bio Company Profile and Key Stats
Latest funding round on record: May 2026.
Annovis Bio Funding Rounds
Annovis Bio raised $8.7M in an undisclosed round announced in Apr 2023.
1.8 years later, an undisclosed round of $21.0M was announced in Feb 2025.
8 months later, an undisclosed round of $3.4M was announced in Oct 2025.
6 months later, an undisclosed round of $10.0M was announced in Apr 2026.
1 month later, an undisclosed round of $15.0M was announced in May 2026.
Annovis Bio Founders and Leadership Team
Contact details for the Annovis Bio team: 1 of 2 have an email address on file.
Start 14-day free trial →Annovis Bio Funding Compared to Other Biotechnology Startups
Annovis Bio's latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Annovis Bio in Biotechnology and Berwyn
Companies Similar to Annovis Bio
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Annovis Bio Funding FAQs
What does Annovis Bio do?
Annovis Bio is a pharmaceutical company focused on creating new therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. They are working on two drugs: Posiphen®, which aims to treat early stages of AD and PD to potentially slow the disease progression, and BNC, which targets late-stage AD to potentially stabilize cognitive decline.
How much funding has Annovis Bio raised?
Annovis Bio has raised $58.1M across 5 rounds on record. The most recent is an undisclosed round of $15.0M announced in May 2026.
When did Annovis Bio last raise funding?
Annovis Bio's most recent funding round on record is an undisclosed round of $15.0M, announced in May 2026.
Who founded Annovis Bio?
FundedIQ lists Maria L (Founder), Maria Maccecchini (Founder) at Annovis Bio.
Where is Annovis Bio headquartered?
Annovis Bio is based in Berwyn, Pennsylvania, United States.
How many employees does Annovis Bio have?
Annovis Bio is in the 1-10 employee band.
How does Annovis Bio's funding compare to other Biotechnology startups?
Annovis Bio's latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Annovis Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Annovis Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.